Daily News: Aging

Findings from University of Alabama Provide New Insights into Clinical Trials and Studies

NewsRx.com

09-20-13

By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators publish new report on Clinical Research. According to news reporting out of Birmingham, Alabama, by NewsRx editors, research stated, "Observational studies have shown benefit of hormone therapy, particularly estrogen, in women who begin treatment in the perimenopausal/early postmenopausal period, whereas randomized controlled trials of such therapy in older postmenopausal women have reported harm. These apparently paradoxical findings have led to the 'timing hypothesis' which proposes that estrogen signaling is altered in older women, converting vasoprotective to vasotoxic effects."

Our news journalists obtained a quote from the research from the University of Alabama, "We reviewed recent literature on age-dependent effects of hormones (particularly estrogen) on the vasculature of women and the fundamental cellular/molecular mechanisms responsible for those effects. Observational studies have shown that early menopause is associated with adverse cardiovascular disease outcomes and that starting hormone therapy in the perimenopausal period reduces these outcomes. Mechanistic studies have shown that estrogen modulates injury-induced inflammation, growth factor expression, and oxidative stress in arteries and vascular smooth muscle cells isolated from young women but that these vasoprotective mechanisms are lost in women who are aged and/or deprived of estrogen for prolonged periods of time. The vasoprotective effects of estrogen are age-dependent and disappear with aging and/or estrogen deprivation."

According to the news editors, the research concluded: "Future studies designed to preserve the vasoprotective effects of estrogen in older women are needed and may lead to innovative approaches to improving women's cardiovascular health."

For more information on this research see: Ovarian hormones and vascular disease. Current Opinion In Cardiology, 2013;28(4):411-6. (Lippincott Williams and Wilkins - www.lww.com; Current Opinion In Cardiology - journals.lww.com/co-cardiology/pages/default.aspx)

Our news journalists report that additional information may be obtained by contacting F.G. Hage, Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, Dept. of Medicine, School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, United States (see also Clinical Research).

Keywords for this news article include: Alabama, Therapy, Hormones, Estrogens, Birmingham, Gynecology, Hematology, United States, Endocrinology, Women's Health, Clinical Research, Cardiovascular Diseases, North and Central America, Clinical Trials and Studies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC

To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .

Articles featured in Life Extension Daily News are derived from a variety of news sources and are provided as a service by Life Extension. These articles, while of potential interest to readers of Life Extension Daily News, do not necessarily represent the opinions nor constitute the advice of Life Extension.